Keytruda. Keytruda (pembrolizumab) Description
|
|
- Abel Stokes
- 6 years ago
- Views:
Transcription
1 Federal Employee Program 1310 G Street, N.W. Washington, D.C Fax Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda (pembrolizumab) Background Keytruda is a monoclonal antibody for the treatment of patients with advanced or unresectable melanoma, metastatic non-small cell lung cancer (NSCLC), metastatic nonsquamous non-small cell lung cancer (NSCLC), recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), and refractory classical Hodgkin lymphoma (chl), recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, and microsatellite instabilityhigh or mismatch repair deficient solid tumors that have progressed following prior treatments. Keytruda blocks a cellular pathway known as PD-1, human programmed death receptor-1, which restricts the body s immune system from attacking cancer cells (1-3). Regulatory Status FDA-approved indication: Keytruda is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: (3) 1. Patients with unresectable or metastatic melanoma 2. Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) 50%)] as determined by an FDAapproved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC 3. Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD- L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda
2 Subject: Keytruda Page: 2 of 7 4. In combination with pemetrexed and carboplatin, as first-line treatment of patients with metastatic nonsquamous NSCLC 5. Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy 6. Adult and pediatric patients with refractory classical Hodgkin lymphoma (chl), or who have relapsed after 3 or more prior lines of therapy 7. Patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 8. Adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. 9. Patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) 1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy Limitations of Use: The safety and effectiveness of Keytruda in pediatric patients with MSI-H central nervous system cancers have not been established (3). This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials (3). Clinically significant immune-mediated adverse reactions may occur with Keytruda therapy including pneumonitis, colitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism. Based on the severity of the adverse reaction, Keytruda should be withheld or discontinued and corticosteroids administered. Patients should be monitored for signs and symptoms of pneumonitis, colitis, hypophysitis, thyroid disorders, and changes in liver and renal function. Keytruda may cause fetal harm when administered to a pregnant woman. Female patients of reproductive potential should be advised of the potential hazard to a fetus (3). Safety and effectiveness of Keytruda have been established in pediatric patients (3).
3 Subject: Keytruda Page: 3 of 7 Related Policies Alecensa, Avastin, Cotellic, Cyramza, Gilotrif, Imlygic, Iressa, Mekinist, Opdivo, Portrazza, Sylatron, Tafinlar, Tagrisso, Tarceva, Tecentriq, Xalkori, Yervoy, Zelboraf, Zykadia Policy This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims. Keytruda may be considered medically necessary in patients with unresectable or metastatic melanoma, for metastatic non-small cell lung cancer (NSCLC), for metastatic nonsquamous non-small cell lung cancer (NSCLC), for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), patients with refractory classical Hodgkin lymphoma (chl),advanced or metastatic urothelial carcinoma, microsatellite instability-high (MSI-H) or a mismatch repair deficient (dmmr) solid tumors, or recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma; and if the conditions indicated below are met. Keytruda is considered investigational in patients with all other indications. Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Unresectable or metastatic melanoma 2. Metastatic non-small cell lung cancer (NSCLC) with ONE of the following: a. PD-L1 tumor expression with Tumor Proportion Score (TPS) 50% determined by a FDA-approved test i. Negative for EGFR or ALK tumor expression b. PD-L1 tumor expression with Tumor Proportion Score (TPS) 1% determined by a FDA-approved test with ONE of the following: i. Negative for EGFR or ALK tumor expression 1) Disease progression on or after platinum-containing chemotherapy ii. Positive EGFR or ALK tumor expression 2) Disease progression after targeted FDA-approved therapy
4 Subject: Keytruda Page: 4 of 7 3. Metastatic nonsquamous non-small cell lung cancer (NSCLC) a. Used in combination with pemetrexed and carboplatin 4. Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) a. Disease progression on or after platinum-containing chemotherapy 5. Refractory classical Hodgkin lymphoma (chl) a. Patient has relapsed after 3 or more prior lines of therapy 6. Advanced or metastatic urothelial carcinoma with ONE of the following: a. Patient is NOT eligible for cisplatin-containing chemotherapy b. Disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy 7. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) cancers with ONE of the following: a. Solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options i. NOT for use in pediatric patients with MSI-H central nervous system cancers b. Colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan AND the following for MSI-H or dmmr cancers: a. Diagnosis has to be confirmed by PCR-based assay genetic testing 8. Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma a. PD-L1 tumor expression with combined positive score (CPS) 1 as determined by an FDA-approved test b. Disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy Prior Approval Renewal Requirements Diagnoses
5 Subject: Keytruda Page: 5 of 7 Patient must have ONE of the following: 1. Unresectable or metastatic melanoma 2. Metastatic non-small cell lung cancer (NSCLC) 3. Metastatic nonsquamous non-small cell lung cancer (NSCLC) 4. Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) 5. Refractory classical Hodgkin lymphoma (chl) 6. Advanced or metastatic urothelial carcinoma 7. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) cancers a. NOT for use in pediatric patients with MSI-H central nervous system cancers 8. Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma AND the following: a. Prescriber agrees to discontinue treatment for any immune mediated adverse reaction (encephalitis, nephritis, rash, decreased renal function and endocrinopathies) or disease progression Policy Guidelines Pre - PA Allowance None Prior - Approval Limits Duration 6 months Prior Approval Renewal Limits Duration 12 months Rationale Summary Keytruda is a monoclonal antibody indicated for the treatment of patients with advanced or unresectable melanoma, metastatic non-small cell lung cancer (NSCLC), metastatic nonsquamous non-small cell lung cancer (NSCLC), recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), refractory classical Hodgkin lymphoma (chl) who are no longer responding to other drugs, locally advanced or metastatic urothelial carcinoma, recurrent
6 Subject: Keytruda Page: 6 of 7 locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, and microsatellite instability-high or mismatch repair deficient solid tumors that have progressed following prior treatments. Clinically significant immune-mediated adverse reactions may occur with Keytruda therapy including pneumonitis, colitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism. Based on the severity of the adverse reaction, Keytruda should be withheld or discontinued and corticosteroids administered. Keytruda may cause fetal harm when administered to a pregnant woman. Safety and effectiveness of Keytruda have been established in pediatric patients (1-3). Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Keytruda while maintaining optimal therapeutic outcomes. References 1. NCCN Clinical Practice Guidelines in Oncology Melanoma (Version ). National Comprehensive Cancer Network, Inc. October NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer (Version ). National Comprehensive Cancer Network, Inc. October Keytruda [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp. September Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for determination of microstatellite instability in colorectal cancer. Cancer Res Nov 15;58(22): Policy History Date September 2014 December 2014 June 2015 October 2015 December 2015 Action New Policy Annual editorial review and reference update Annual editorial review Addition of Metastatic non-small cell lung cancer (NSCLC) if the patient has PD-L1 tumor expression determined by a FDA-approved test and has disease progression on or after platinum-containing chemotherapy; or the patient has EGFR or ALK tumor expression and has disease progression after FDA-approved therapy Removal of disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor and no concurrent therapy with other agents for the treatment of unresectable or metastatic
7 Subject: Keytruda Page: 7 of 7 March 2016 June 2016 August 2016 September 2016 November 2016 December 2016 March 2017 June 2017 July 2017 September 2017 October 2017 December 2017 Keywords melanoma Annual editorial review Policy number change from to Annual editorial review Addition of Prescriber agrees to discontinue treatment for any immune mediated adverse reaction (encephalitis, nephritis, rash, decreased renal function and endocrinopathies) or disease progression in renewal section per SME Addition of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinumcontaining chemotherapy Addition of (NSCLC) PD-L1 tumor expression with Tumor Proportion Score (TPS) 50% determined by a FDA-approved test with no prior treatment needed Addition of refractory classical Hodgkin lymphoma (chl), who have relapsed after 3 or more prior lines of therapy Removal of the age requirement Annual editorial review and reference update Addition of metastatic nonsquamous non-small cell lung cancer (NSCLC) Addition of advanced or metastatic urothelial carcinoma Addition of Microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) cancers with additional requirements to criteria Addition of the requirement to MSI-H: diagnosis has to be confirmed by PCR-based genetic testing Addition of recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma This policy was approved by the FEP Pharmacy and Medical Policy Committee on December 8, 2017 and is effective on January 1, 2018.
Keytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationTecentriq. Tecentriq (atezolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.80 Subject: Tecentriq Page: 1 of 5 Last Review Date: September 15, 2017 Tecentriq Description Tecentriq
More information2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 5 Last Review Date: September 15, 2017 Gilotrif Description Gilotrif
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)
More information2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 5 Last Review Date: June 24, 2016 Gilotrif Description Gilotrif (afatinib)
More informationCyramza. Cyramza (ramucirumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: September 15, 2017 Cyramza Description Cyramza
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationGilotrif. Gilotrif (afatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 6 Last Review Date: March 16, 2018 Gilotrif Description Gilotrif (afatinib)
More informationMekinist. Mekinist (trametinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.38 Subject: Mekinist Page: 1 of 6 Last Review Date: June 22, 2017 Mekinist Description Mekinist (trametinib)
More informationCyramza. Cyramza (ramucirumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: June 24, 2016 Cyramza Description Cyramza (ramucirumab)
More informationXalkori. Xalkori (crizotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.12 Subject: Xalkori Page: 1 of 6 Last Review Date: June 22, 2017 Xalkori Description Xalkori (crizotinib)
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 4 Last Review Date: March 18, 2016 Yervoy Description Yervoy (ipilimumab)
More informationTagrisso. Tagrisso (osimertinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.69 Subject: Tagrisso Page: 1 of 5 Last Review Date: September 15, 2016 Tagrisso Description Tagrisso
More informationPortrazza. Portrazza (necitumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.72 Subject: Portrazza Page: 1 of 5 Last Review Date: September 15, 2017 Portrazza Description Portrazza
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03.01.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMedia Contacts: Pamela Eisele Investor Contacts: Teri Loxam (267)
News Release FOR IMMEDIATE RELEASE Media Contacts: Pamela Eisele Investor Contacts: Teri Loxam (267) 305-3558 (908) 740-1986 Ann Bush (908) 740-6677 Amy Klug (908) 740-1898 FDA Approves Merck s KEYTRUDA
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May
BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationMEDICATION GUIDE. KEYTRUDA (key-true-duh) (pembrolizumab) for injection
(key-true-duh) (pembrolizumab) for injection MEDICATION GUIDE (key-true-duh) (pembrolizumab) injection What is the most important information I should know about? is a medicine that may treat certain cancers
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationLimitations of Use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.66 Subject: Imlygic Page: 1 of 5 Last Review Date: June 22, 2017 Imlygic Description Imlygic (talimogene
More informationMay 31, NCCN Guidelines: T-Cell Lymphomas
May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively. See full prescribing information for OPDIVO. OPDIVO (nivolumab) injection,
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin
More informationVectibix. Vectibix (panitumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix
More informationTafinlar. Tafinlar (dabrafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.37 Subject: Tafinlar Page: 1 of 8 Last Review Date: September 20, 2018 Tafinlar Description Tafinlar
More informationIressa. Iressa (gefitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Iressa Page: 1 of 5 Last Review Date: June 22, 2018 Iressa Description Iressa (gefitinib) Background
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationUnderstanding your treatment and the side effects you may experience
Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has
More informationZydelig. Zydelig (idelalisib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2018 Zydelig Description Zydelig (idelalisib)
More informationZydelig. Zydelig (idelalisib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2017 Zydelig Description Zydelig (idelalisib)
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.04 Subject: Avastin Page: 1 of 8 Last Review Date: December 3, 2015 Avastin Description Avastin (bevacizumab)
More informationGilotrif. Gilotrif (afatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.39 Subject: Gilotrif Page: 1 of 5 Last Review Date: September 12, 2014 Gilotrif Description Gilotrif
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationClinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322
Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationBLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125554/S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL Bristol-Myers
More informationCyramza (ramucirumab)
Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationNexavar. Nexavar (sorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.60 Section: Prescription Drugs Effective Date: July 1,2017 Subject: Nexavar Page: 1 of 5 Last Review
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 5 Last Review Date: September 15, 2017 Sutent Description Sutent (sunitinib)
More informationCalquence. Calquence (acalabrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.106 Subject: Calquence Page: 1 of 5 Last Review Date: March 16, 2018 Calquence Description Calquence
More informationTafinlar. Tafinlar (dabrafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.37 Subject: Tafinlar Page: 1 of 6 Last Review Date: June 19, 2015 Tafinlar Description Tafinlar (dabrafenib)
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationStivarga. Stivarga (regorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.26 Subject: Stivarga Page: 1 of 5 Last Review Date: September 15, 2017 Stivarga Description Stivarga
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationClinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17
Clinical Policy: (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationAttached from the following page is the press release made by BMS for your information.
September 17, 2015 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma (PRINCETON, NJ, September
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT
PAGE 175 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT Summary of risk management plan for pembrolizumab This is a summary of the risk management plan (RMP) for pembrolizumab. The RMP details
More informationNews Release FOR IMMEDIATE RELEASE (908) (267) Amy Klug (908) Courtney Ronaldo (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Pamela Eisele (267) 305-3558 Investor Contacts: Teri Loxam (908) 740-1986 Courtney Ronaldo (908) 236-1108 Amy Klug (908) 740-1898 FDA Approves Merck s
More informationSiklos. Siklos (hydroxyurea) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.27 Subject: Siklos Page: 1 of 5 Last Review Date: November 30, 2018 Siklos Description Siklos (hydroxyurea)
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 6 Last Review Date: March 16, 2018 Sutent Description Sutent (sunitinib)
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationDrug Prior Authorization Form Opdivo (nivolumab)
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
BAVENCIO (avelumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)
September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationLimitation of use: Onivyde is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Onivyde Page: 1 of 5 Last Review Date: June 24, 2016 Onivyde Description Onivyde (irinotecan liposome
More informationBristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma
December 2, 2015 Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma (PRINCETON, NJ, November 27, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced that the
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationCyramza. Cyramza (ramucirumab) Description. Section: Prescription Drugs Effective Date: October 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cyramza Page: 1 of 5 Last Review Date: September 12, 2014 Cyramza Description Cyramza (ramucirumab)
More informationContacts: Media Pamela Eisele ( ); Investor Teri Loxam ( )
News Release FOR IMMEDIATE RELEASE Contacts: Media Pamela Eisele (267-305-3558); Investor Teri Loxam (908-740-1986) FDA Approves Merck s KEYTRUDA (pembrolizumab) as First-Line Combination Therapy with
More informationPembrolizumab 200mg Monotherapy
Pembrolizumab 200mg This regimen supercedes NCCP Regimen 00347 Pembrolizumab 2mg/kg as of September 2018 due to a change in the licensed dosing posology. INDICATIONS FOR USE: INDICATION ICD10 Regimen Code
More informationRegulatory Status FDA-approved indications: Emend is a substance P/neurokinin 1 (NK1) receptor antagonist, indicated: (1-2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.05 Section: Prescription Drugs Effective Date: April 1, 2017 Subject: Emend Page: 1 of 6 Last Review
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION KEYTRUDA has been issued marketing authorization with conditions for the following patients, pending the results of
More informationImmune-Mediated Adverse Reactions Management Guide
Immune-Mediated Adverse Reactions Management Guide Please see Important Safety Information for OPDIVO on pages 35 39 and US Full Prescribing Information for OPDIVO. Please refer to the end of the Important
More informationAttached from the following page is the press release made by BMS for your information.
September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationTykerb. Tykerb (lapatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.23 Subject: Tykerb Page: 1 of 5 Last Review Date: December 8, 2017 Tykerb Description Tykerb (lapatinib)
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationAbout TARIS System and TAR-200 (GemRIS )
TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration Phase 1b Study to Combine TAR-200 (GemRIS ) with Opdivo (nivolumab) in the Treatment of Muscle Invasive Bladder Cancer LEXINGTON, Mass.
More informationBristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
January 20, 2017 Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer (PRINCETON, NJ, January 19, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) announced that it has decided not
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma (PRINCETON,
More informationKEYTRUDA Pembrolizumab
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA Pembrolizumab powder for solution for infusion 50 mg solution for infusion 100 mg/4ml vial Antineoplastic agent, monoclonal antibody
More information